Literature DB >> 34499116

Dihydroartemisinin-Piperaquine Chemoprevention and Malaria Incidence After Severe Flooding: Evaluation of a Pragmatic Intervention in Rural Uganda.

Ross M Boyce1,2,3, Brandon D Hollingsworth1, Emma Baguma4, Erin Xu5, Varun Goel3,6, Amanda Brown-Marusiak2, Rabbison Muhindo4, Raquel Reyes7, Moses Ntaro4, Mark J Siedner8, Sarah G Staedke9, Jonathan J Juliano1,2, Edgar M Mulogo4.   

Abstract

BACKGROUND: Malaria epidemics are a well-described phenomenon after extreme precipitation and flooding. Yet, few studies have examined mitigation measures to prevent post-flood malaria epidemics.
METHODS: We evaluated a malaria chemoprevention program implemented in response to severe flooding in western Uganda. Children aged ≤12 years from 1 village were eligible to receive 3 monthly rounds of dihydroartemisinin-piperaquine (DP). Two neighboring villages served as controls. Malaria cases were defined as individuals with a positive rapid diagnostic test result as recorded in health center registers. We performed a difference-in-differences analysis to estimate changes in the incidence and test positivity of malaria between intervention and control villages.
RESULTS: A total of 554 children received at least 1 round of chemoprevention, with 75% participating in at least 2 rounds. Compared with control villages, we estimated a 53.4% reduction (adjusted rate ratio [aRR], 0.47; 95% confidence interval [CI]: .34-.62; P < .01) in malaria incidence and a 30% decrease in the test positivity rate (aRR, 0.70; 95% CI: .50-.97; P = .03) in the intervention village in the 6 months post-intervention. The impact was greatest among children who received the intervention, but decreased incidence was also observed in older children and adults (aRR, 0.57; 95% CI: .38-.84; P < .01).
CONCLUSIONS: Three rounds of chemoprevention with DP delivered under pragmatic conditions reduced the incidence of malaria after severe flooding in western Uganda. These findings provide a proof-of-concept for the use of malaria chemoprevention to reduce excess disease burden associated with severe flooding.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Plasmodiumzzm321990 ; chemoprevention; flooding; malaria; mass drug administration

Mesh:

Substances:

Year:  2022        PMID: 34499116      PMCID: PMC9258940          DOI: 10.1093/cid/ciab781

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  33 in total

1.  Climate change and human health: impacts, vulnerability, and mitigation.

Authors:  A Haines; R S Kovats; D Campbell-Lendrum; C Corvalan
Journal:  Lancet       Date:  2006-06-24       Impact factor: 79.321

2.  First look at changes in flood hazard in the Inter-Sectoral Impact Model Intercomparison Project ensemble.

Authors:  Rutger Dankers; Nigel W Arnell; Douglas B Clark; Pete D Falloon; Balázs M Fekete; Simon N Gosling; Jens Heinke; Hyungjun Kim; Yoshimitsu Masaki; Yusuke Satoh; Tobias Stacke; Yoshihide Wada; Dominik Wisser
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205

3.  Epidemic of malaria in north-eastern Kenya.

Authors:  V Brown; M Abdir Issak; M Rossi; P Barboza; A Paugam
Journal:  Lancet       Date:  1998-10-24       Impact factor: 79.321

4.  Post-flood--infectious diseases in Mozambique.

Authors:  Hisayoshi Kondo; Norimasa Seo; Tadashi Yasuda; Masahiro Hasizume; Yuichi Koido; Norifumi Ninomiya; Yasuhiro Yamamoto
Journal:  Prehosp Disaster Med       Date:  2002 Jul-Sep       Impact factor: 2.040

5.  Severe Flooding and Malaria Transmission in the Western Ugandan Highlands: Implications for Disease Control in an Era of Global Climate Change.

Authors:  Ross Boyce; Raquel Reyes; Michael Matte; Moses Ntaro; Edgar Mulogo; Joshua P Metlay; Lawrence Band; Mark J Siedner
Journal:  J Infect Dis       Date:  2016-08-17       Impact factor: 5.226

Review 6.  Intermittent preventive treatment for malaria in children living in areas with seasonal transmission.

Authors:  Martin M Meremikwu; Sarah Donegan; David Sinclair; Ekpereonne Esu; Chioma Oringanje
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

7.  Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial.

Authors:  Thomas P Eisele; Adam Bennett; Kafula Silumbe; Timothy P Finn; Victor Chalwe; Mulakwa Kamuliwo; Busiku Hamainza; Hawela Moonga; Emmanuel Kooma; Elizabeth Chizema Kawesha; Joshua Yukich; Joseph Keating; Travis Porter; Ruben O Conner; Duncan Earle; Richard W Steketee; John M Miller
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

Review 8.  Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis.

Authors:  Julie Gutman; Stephanie Kovacs; Grant Dorsey; Andy Stergachis; Feiko O Ter Kuile
Journal:  Lancet Infect Dis       Date:  2016-11-17       Impact factor: 25.071

9.  Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of differing transmission intensity.

Authors:  Bronner P Gonçalves; Melissa C Kapulu; Patrick Sawa; Wamdaogo M Guelbéogo; Alfred B Tiono; Lynn Grignard; Will Stone; Joel Hellewell; Kjerstin Lanke; Guido J H Bastiaens; John Bradley; Issa Nébié; Joyce M Ngoi; Robin Oriango; Dora Mkabili; Maureen Nyaurah; Janet Midega; Dyann F Wirth; Kevin Marsh; Thomas S Churcher; Philip Bejon; Sodiomon B Sirima; Chris Drakeley; Teun Bousema
Journal:  Nat Commun       Date:  2017-10-26       Impact factor: 14.919

10.  Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial.

Authors:  Michelle S Hsiang; Henry Ntuku; Kathryn W Roberts; Mi-Suk Kang Dufour; Brooke Whittemore; Munyaradzi Tambo; Patrick McCreesh; Oliver F Medzihradsky; Lisa M Prach; Griffith Siloka; Noel Siame; Cara Smith Gueye; Leah Schrubbe; Lindsey Wu; Valerie Scott; Sofonias Tessema; Bryan Greenhouse; Erica Erlank; Lizette L Koekemoer; Hugh J W Sturrock; Agnes Mwilima; Stark Katokele; Petrina Uusiku; Adam Bennett; Jennifer L Smith; Immo Kleinschmidt; Davis Mumbengegwi; Roly Gosling
Journal:  Lancet       Date:  2020-04-25       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.